Multiple upgrades post earnings
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.66.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 49.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Aileron Therapeutics is a Strong Buy with an average price target of $4.33, implying a 633.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.
Recent upgrade source smateranalyst
Company profile
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.66.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 49.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Aileron Therapeutics is a Strong Buy with an average price target of $4.33, implying a 633.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.
Recent upgrade source smateranalyst
Company profile
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.